Sensei Biotherapeutics (NASDAQ:FTH) Earns Buy Rating from Analysts at HC Wainwright

Research analysts at HC Wainwright initiated coverage on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research report issued on Monday,Benzinga reports. The firm set a “buy” rating and a $60.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 236.70% from the stock’s previous close.

FTH has been the topic of several other research reports. BTIG Research raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a report on Wednesday. They issued a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $60.00.

Sensei Biotherapeutics Stock Performance

FTH opened at $17.82 on Monday. Sensei Biotherapeutics has a 12-month low of $6.32 and a 12-month high of $36.76. The stock has a market cap of $23.88 million, a P/E ratio of -0.12 and a beta of -0.25.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.